Biotest AG (DE:BIO3)
XETRA:BIO3
Holding DE:BIO3?
Track your performance easily

Biotest (BIO3) Income Statement

2 Followers

Biotest Income Statement

Last quarter (Q4 2022), Biotest's total revenue was €155.30M, an increase of 7.70% from the same quarter last year. In Q4, Biotest's net income was €2.10M. See Biotest’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
€ 516.10M€ 516.10M€ 515.60M€ 484.20M€ 419.10M€ 400.30M
Cost of Revenue
€ 391.30M€ 391.20M€ 434.90M€ 354.10M€ 290.30M€ 265.50M
Gross Profit
€ 124.80M€ 124.90M€ 80.70M€ 130.10M€ 128.80M€ 134.80M
Operating Expense
€ 139.90M€ 133.40M€ 132.80M€ 132.60M€ 135.50M€ 132.30M
Operating Income
€ -15.10M€ -8.50M€ -52.10M€ -2.50M€ -6.70M€ 2.50M
Net Non Operating Interest Income Expense
€ -22.70M€ -22.80M€ -15.70M€ -15.80M€ -10.70M€ -16.50M
Other Income Expense
------
Pretax Income
€ -30.80M€ -30.80M€ -62.60M€ -30.00M€ -1.30M€ -6.00M
Tax Provision
€ 800.00K€ 800.00K€ 700.00K€ 1.40M€ 3.40M€ 6.90M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ -32.10M€ -32.10M€ -63.80M€ -31.80M€ -5.10M€ 181.30M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
€ 531.20M€ 524.60M€ 567.70M€ 486.70M€ 425.80M€ 397.80M
Net Income From Continuing And Discontinued Operation
€ -31.70M€ -31.70M€ -63.40M€ -31.40M€ -4.70M€ 181.70M
Normalized Income
€ -31.70M€ -32.84M€ -65.08M€ -29.58M€ -15.83M€ -15.00M
Interest Expense
€ 19.60M€ 19.70M€ 13.20M€ 14.20M€ 10.70M€ 10.90M
EBIT
€ -11.20M€ -11.10M€ -49.40M€ -15.80M€ 9.40M€ 4.90M
EBITDA
€ -11.20M€ 24.70M€ -18.30M€ 13.90M€ 41.10M€ 29.60M
Currency in EUR

Biotest Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis